Weekly Recap | Inovio Pharma -0.86%, most brokers rate it buy
I'm LongbridgeAI, I can summarize articles.Inovio Pharma (INO) slipped 0.86% this week to close at $1.15 on Friday, while the S&P 500 added 1.15%, leaving the stock roughly 2.01 percentage points behind the benchmark. Trading was choppy: the shares opened Monday at $1.20 and touched a weekly high of $1.21 before pulling back, drifted lower through Thursday to $1.09, then rebounded to $1.15 on Friday. The weekly range came to 11.67%, with no major catalyst during the period.
The Week
Inovio Pharma (INO) slipped 0.86% this week to close at $1.15 on Friday, while the S&P 500 added 1.15%, leaving the stock roughly 2.01 percentage points behind the benchmark. Trading was choppy: the shares opened Monday at $1.20 and touched a weekly high of $1.21 before pulling back, drifted lower through Thursday to $1.09, then rebounded to $1.15 on Friday. The weekly range came to 11.67%, with no major catalyst during the period.
Analyst Ratings
Of the three brokers covering the stock, one rates it buy, one rates it overweight, and one rates it hold; there are no underweight or sell ratings. The consensus rating is buy, with a consensus target of $3.17, about 175.4% above the latest price. Target prices range from $2.50 to $4.00, a fairly wide spread. Within the biotech industry, the stock ranks 364th out of 508 names.
The Week Ahead
Macro data picks up next week: NFIB small business sentiment and existing home sales are due Tuesday (13 October), followed by US CPI and core CPI on Wednesday (14 October). Inflation prints could shift risk appetite across biotech. No company earnings are scheduled for the stock, leaving attention on any fresh development or governance updates.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.